Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.
Soulières D, Faivre S, Mesía R, Remenár É, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, Nagarkar R, Tamás L, Kim SB, Erfán J, Alyasova A, Kasper S, Barone C, Turri S, Chakravartty A, Chol M, Aimone P, Hirawat S, Licitra L. Soulières D, et al. Among authors: ochsenreither s. Lancet Oncol. 2017 Mar;18(3):323-335. doi: 10.1016/S1470-2045(17)30064-5. Epub 2017 Jan 26. Lancet Oncol. 2017. PMID: 28131786 Clinical Trial.
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study.
Klinghammer K, Fayette J, Kawecki A, Dietz A, Schafhausen P, Folprecht G, Rottey S, Debourdeau P, Lavernia J, Jacobs A, Ahrens-Fath I, Dietrich B, Baumeister H, Zurlo A, Ochsenreither S, Keilholz U. Klinghammer K, et al. Among authors: ochsenreither s. ESMO Open. 2021 Oct;6(5):100242. doi: 10.1016/j.esmoop.2021.100242. Epub 2021 Sep 2. ESMO Open. 2021. PMID: 34482179 Free PMC article. Clinical Trial.
[Immunotherapy Against Head and Neck Cancer Stem Cells].
Coordes A, Ochsenreither S, Qian X, Hofmann VM, Meyer JE, Karl Hoffmann T, Kaufmann AM, Albers AE. Coordes A, et al. Among authors: ochsenreither s. Laryngorhinootologie. 2017 Apr;96(4):216-224. doi: 10.1055/s-0043-101698. Epub 2017 May 10. Laryngorhinootologie. 2017. PMID: 28493252 Review. German.
pN status predicts outcomes in surgically treated pT1-pT2 patients of various disease stages with squamous cell carcinoma of the head and neck: a 17-year retrospective single center cohort study.
Qian X, Sinikovic B, Schreiber F, Ochsenreither S, Klinghammer K, Wollenberg B, Kaufmann AM, Albers AE. Qian X, et al. Among authors: ochsenreither s. Eur Arch Otorhinolaryngol. 2018 Nov;275(11):2787-2795. doi: 10.1007/s00405-018-5108-z. Epub 2018 Aug 29. Eur Arch Otorhinolaryngol. 2018. PMID: 30159726
63 results